Ranger Paclitaxel-Coated PTA Balloon Catheter
BOSTON SCIENTIFIC CORPORATION · Decision date Mar 12, 2026
What did the FDA decide?
FDA records P190019/S041 as a supplement to PMA P190019, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Mar 12, 2026.
FDA approval order statement
introduction of an additional Ranger DCB balloon coating line (Line 15) at Hemoteq AG
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Mar 12, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P190019/S041
- Regulatory pathway
- PMA supplement
- Applicant
- BOSTON SCIENTIFIC CORPORATION
- Product code
- ONU
- Decision code
- OK30
- Decision date
- Mar 12, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Drug-Eluting Peripheral Transluminal Angioplasty Catheter.
- Applicant
- Boston Scientific Corporation
- Product code
- ONU
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P190019/S039 · Related supplement
Ranger Paclitaxel-Coated PTA Balloon Catheter
P190019/S041 received
Application receipt date recorded by FDA.
P190019/S041 · FDA decision
30-Day Notice
P190019/S042 · Related supplement
RANGER Paclitaxel-Coated PTA Balloon Catheter
P190019/S040 · Related supplement
Ranger Paclitaxel-Coated PTA Balloon Catheter
P190019/S043 · Related supplement
Ranger Paclitaxel-Coated Balloon Catheter
Timeline entries are records held by MedtechLedger for P190019. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P190019
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Ranger Paclitaxel-Coated PTA Balloon CatheterP190019/S039 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Oct 24, 2025 | FDA |
RANGER Paclitaxel-Coated PTA Balloon CatheterP190019/S042 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Apr 24, 2026 | FDA |
Ranger Paclitaxel-Coated PTA Balloon CatheterP190019/S040 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | May 1, 2026 | FDA |
Ranger Paclitaxel-Coated Balloon CatheterP190019/S043 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Aug 4, 2026 | FDA |
Explore the linked device profile
Other records with product code ONU
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA supplement | Sep 24, 2026 | FDA | |
Lutonix 035 Drug Coated Balloon CatheterP130024/S045 | Lutonix | PMA supplement | Jul 9, 2026 | FDA |
| Medtronic, Inc. | PMA supplement | May 28, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | May 21, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | May 1, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Corporation
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- Three Scimed Pl., Maple Grove, MN, 55311
Sources and methodology
- Original FDA record: P190019/S041
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records